| Classifying cancers based on T-cell infiltration and PD-L1 MWL Teng, SF Ngiow, A Ribas, MJ Smyth Cancer research 75 (11), 2139-2145, 2015 | 1443 | 2015 |
| TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion O Khan, JR Giles, S McDonald, S Manne, SF Ngiow, KP Patel, MT Werner, ... Nature 571 (7764), 211-218, 2019 | 1110 | 2019 |
| Combination cancer immunotherapies tailored to the tumour microenvironment MJ Smyth, SF Ngiow, A Ribas, MWL Teng Nature reviews Clinical oncology 13 (3), 143-158, 2016 | 906 | 2016 |
| Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease J Liu, SJ Blake, MCR Yong, H Harjunpää, SF Ngiow, K Takeda, A Young, ... Cancer discovery 6 (12), 1382-1399, 2016 | 693 | 2016 |
| Anti-TIM3 antibody promotes T cell IFN-γ–mediated antitumor immunity and suppresses established tumors SF Ngiow, B Von Scheidt, H Akiba, H Yagita, MWL Teng, MJ Smyth Cancer research 71 (10), 3540-3551, 2011 | 651 | 2011 |
| Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms JC Beltra, S Manne, MS Abdel-Hakeem, M Kurachi, JR Giles, Z Chen, ... Immunity 52 (5), 825-841. e8, 2020 | 581 | 2020 |
| Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells Y Gao, F Souza-Fonseca-Guimaraes, T Bald, SS Ng, A Young, SF Ngiow, ... Nature immunology 18 (9), 1004-1015, 2017 | 552 | 2017 |
| Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy J Stagg, S Loi, U Divisekera, SF Ngiow, H Duret, H Yagita, MW Teng, ... Proceedings of the National Academy of Sciences 108 (17), 7142-7147, 2011 | 551 | 2011 |
| TIGIT predominantly regulates the immune response via regulatory T cells S Kurtulus, K Sakuishi, SF Ngiow, N Joller, DJ Tan, MWL Teng, MJ Smyth, ... The Journal of clinical investigation 125 (11), 4053-4062, 2015 | 543 | 2015 |
| TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision Z Chen, Z Ji, SF Ngiow, S Manne, Z Cai, AC Huang, J Johnson, ... Immunity 51 (5), 840-855. e5, 2019 | 490 | 2019 |
| Cancer immunoediting by the innate immune system in the absence of adaptive immunity T O’Sullivan, R Saddawi-Konefka, W Vermi, CM Koebel, C Arthur, ... The Journal of Experimental Medicine 209 (10), 1869-1882, 2012 | 404 | 2012 |
| Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses A Young, SF Ngiow, DS Barkauskas, E Sult, C Hay, SJ Blake, Q Huang, ... Cancer cell 30 (3), 391-403, 2016 | 359 | 2016 |
| TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer K Sakuishi, SF Ngiow, JM Sullivan, MWL Teng, VK Kuchroo, MJ Smyth, ... Oncoimmunology 2 (4), e23849, 2013 | 332 | 2013 |
| Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma K Klages, CT Mayer, K Lahl, C Loddenkemper, MWL Teng, SF Ngiow, ... Cancer research 70 (20), 7788-7799, 2010 | 305 | 2010 |
| Host immunity contributes to the anti-melanoma activity of BRAF inhibitors DA Knight, SF Ngiow, M Li, T Parmenter, S Mok, A Cass, NM Haynes, ... The Journal of clinical investigation 123 (3), 1371-1381, 2013 | 303 | 2013 |
| A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment A Young, SF Ngiow, Y Gao, AM Patch, DS Barkauskas, M Messaoudene, ... Cancer research 78 (4), 1003-1016, 2018 | 301 | 2018 |
| A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1 SF Ngiow, A Young, N Jacquelot, T Yamazaki, D Enot, L Zitvogel, ... Cancer research 75 (18), 3800-3811, 2015 | 245 | 2015 |
| Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth MWL Teng, SF Ngiow, B Von Scheidt, N McLaughlin, T Sparwasser, ... Cancer research 70 (20), 7800-7809, 2010 | 214 | 2010 |
| Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade N Jacquelot, T Yamazaki, MP Roberti, CPM Duong, MC Andrews, ... Cell research 29 (10), 846-861, 2019 | 198 | 2019 |
| Prospects for TIM3-targeted antitumor immunotherapy SF Ngiow, MWL Teng, MJ Smyth Cancer research 71 (21), 6567-6571, 2011 | 162 | 2011 |
